Agenus AGEN

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.03 (+1.25%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Agenus (AGEN)
    Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.35

    • Market Cap

      $55.49 Million

    • Price-Earnings Ratio

      1.12

    • Total Outstanding Shares

      23.46 Million Shares

    • Total Employees

      389

    • Dividend

      No dividend

    • IPO Date

      February 4, 2000

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      3 forbes road, Lexington, MA, 02421

    • Homepage

      https://www.agenusbio.com

    Historical Stock Splits

    If you bought 120 shares of AGEN before October 3, 2011, you'd have 1 share today.
    Execution DateSplit Amount
    April 12, 20241-for-20 (Reverse Split)
    October 3, 20111-for-6 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$-170.06 Million
    Net Cash Flow From Financing Activities, Continuing$105.78 Million
    Net Cash Flow From Investing Activities, Continuing$2.87 Million
    Net Cash Flow, Continuing$-61.41 Million
    Net Cash Flow From Operating Activities$-170.06 Million
    Net Cash Flow$-61.41 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Cost Of Revenue$628,000
    Gross Profit$159.80 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Preferred Stock Dividends And Other Adjustments$0
    Basic Earnings Per Share$2.10
    Net Income/Loss Attributable To Noncontrolling Interest$-6.40 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Comprehensive Income/Loss$-319,000

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Noncurrent Assets$188.33 Million
    Cash$44.80 Million
    Liabilities And Equity$238.48 Million
    Intangible Assets$3.96 Million
    Prepaid Expenses$2.35 Million
    Equity Attributable To Parent$-292.34 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AGEN from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.